“Shared” Generic Exclusivity In Multi-Patent Cases Speeds Launch – FDA
Executive Summary
Providing shared exclusivity to generic applicants ensures faster access to market for generics, FDA said in explaining its shift from a "patent by patent" approach to 180-day exclusivity
You may also be interested in...
Paxil Generics On Hold After Court Rejects FDA “Shared Exclusivity” Policy
No more generic versions of GlaxoSmithKline's Paxil will be approved before early March under a court decision rejecting FDA's approach to "shared exclusivity.
Paxil Generics On Hold After Court Rejects FDA “Shared Exclusivity” Policy
No more generic versions of GlaxoSmithKline's Paxil will be approved before early March under a court decision rejecting FDA's approach to "shared exclusivity.
Apotex Challenges FDA “Shared” Generic Exclusivity Policy In Paxil Suit
TorPharm is challenging FDA's policy of awarding "shared" 180-day marketing exclusivity to multiple generic companies